

Angio-Seal™  
Vascular Closure Device

---

## RESTICK

FOLLOWING INITIAL ANGIO-SEAL DEVICE USE  
SHOWN TO BE SAFE

Safety of Restick Confirmed  
by Clinical Study



ST. JUDE MEDICAL™  
MORE CONTROL. LESS RISK.

# SAFETY OF RESTICK CONFIRMED IN RESTICK STUDY

The safety and efficacy of a restick of the same artery following an initial Angio-Seal™ Device deployment was evaluated in 181 patients.

## PATIENTS

Patients were included in the study if they had an Angio-Seal™ Device deployment and subsequently underwent arterial access using the same artery that had previously been closed with an Angio-Seal™ Device within 90 days of the original device placement.

## FINDINGS

“The major finding of this study is that arterial restick following initial Angio-Seal™ Device placement can be performed safely without dislodgment of the device and without significant vascular complications.

Moreover, arterial closure of the vessel can be performed safely with a variety of techniques, including a second Angio-Seal™ Device.”<sup>1</sup>



# Restick Labeling Approved for Angio-Seal™ Vascular Closure Device

Labeling has been approved confirming the safety of restick of the same artery following initial Angio-Seal™ Vascular Closure Device use.

“If repuncture at the same location of previous Angio-Seal™ Device use is necessary in < 90 days, reentry 1cm proximal to the previous access site can be performed safely, based on published medical literature.”<sup>1</sup>

## Vascular Complications (N = 181)<sup>1</sup>

		PROPORTION	95% CONFIDENCE INTERVAL
Large hematoma (≥ 10cm)	3	0.0166	0.0043 - 0.0515
Vessel occlusion	0	0	0 - 0.0259
Pseudoaneurysm	0	0	0 - 0.0259
AV fistulae	0	0	0 - 0.0259
Major bleeding	0	0	0 - 0.0259
Vascular repair	0	0	0 - 0.0259
Death	0	0	0 - 0.0259

## Procedural Characteristics (N = 181)<sup>1</sup>

DAYS POST FIRST ANGIO-SEAL™ DEVICE		
1-7	81	(45%)
8-30	34	(19%)
31-90	66	(36%)

<sup>1</sup> Applegate RJ, Rankin KM, Little WC, Kahl FR, Kutcher MA. Restick following initial Angio-Seal™ use. *Catheter Cardiovasc Interv.* Feb 2003;58(2):181-184.

---

“To our knowledge, there are no published reports of attempts to reaccess an artery in which an Angio-Seal™ Device has been deployed, that have led to vascular compromise or loss of hemostasis.”<sup>1</sup>

---

ATRIAL FIBRILLATION

CARDIAC RHYTHM MANAGEMENT

CARDIAC SURGERY

CARDIOLOGY

NEUROMODULATION

**St. Jude Medical**

14901 Deveau Place  
Minnetonka, MN 55345  
952 933 4700  
952 933 0307 Fax

**St. Jude Medical Europe, Inc.**

The Corporate Village  
Avenue Da Vinci laan, 11 - Box F1  
B-1935 - Zaventem  
Belgium  
+32 2 774 68 11  
+32 2 772 83 84 Fax

**St. Jude Medical Brasil, Ltda.**

Rua Frei, Caneca 1380-9º  
A-CJ91/92  
Sao Paulo - SP - Brasil  
CEP 01307-002  
+55 11 5080 5400  
+55 11 5080 5423 Fax

**St. Jude Medical (Hong Kong) Limited**

Unit 2701-07, COSCO Tower  
Grand Millenium Plaza  
183 Queen's Road  
Central, Hong Kong  
+852 2996 7688  
+852 2956 0622 Fax

[www.sjm.com](http://www.sjm.com)



**ST. JUDE MEDICAL**

MORE CONTROL. LESS RISK.

**Rx Only**

**Brief Summary:** Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events, and directions for use.

**Indications:** St. Jude Medical Angio-Seal™ Vascular Closure Device product family, including the STS Plus, VIP and Evolution platforms, is indicated for use in closing and reducing time to hemostasis at the femoral arterial puncture site in patients who have undergone diagnostic angiography procedures or interventional procedures using an 8 French or smaller procedural sheath for the 8F Angio-Seal™ device and a 6 French or smaller procedural sheath for the 6F Angio-Seal™ device. The Angio-Seal™ STS Plus, VIP and Evolution platform devices are also indicated for use to allow patients who have undergone diagnostic angiography to safely ambulate as soon as possible after sheath removal and device placement, as well as to allow patients who have undergone an interventional procedure to safely ambulate after sheath removal and device placement. Possible adverse events for vascular closure devices include, but are not limited to: bleeding or hematoma, AV fistula or pseudoaneurysm, infection, allergic reaction, foreign body reaction, inflammation, or edema.

Angio-Seal, ST. JUDE MEDICAL, the nine-squares symbol and MORE CONTROL. LESS RISK. are trademarks and service marks of St. Jude Medical, Inc. and its related companies. ©2008 St. Jude Medical, Inc. All rights reserved.

Item 41664 Rev.-B

**CE**  
**0044**